Want to see HSCS full AI Analyst Report?
HSCS Stock Chart & Stats
$3.00
-$0.05(-2.05%)
At close: 4:00 PM EDT
$3.00
-$0.05(-2.05%)
Day’s Range― - ―
52-Week Range$1.63 - $5.25
Previous CloseN/A
Volume8.21K
Average Volume (3M)156.59K
Market Cap
$17.69M
Enterprise Value$11.97M
Total Cash (Recent Filing)$29.91M
Total Debt (Recent Filing)$4.00M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Dec 21, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding4,843,910
10 Day Avg. Volume146,331
30 Day Avg. Volume156,593
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)1185.36
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue2.65K
Enterprise Value/Gross Profit-91.09
Enterprise Value/Ebitda-1.28
Forecast
1Y Price Target
$12.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginThe sharp TTM revenue increase and positive gross margin show that the company has begun building a larger commercial base. If sustained, this can support operating leverage and broader product adoption, although current revenue remains modest.
FDA Regulatory ClearanceThe 510(k) clearance expands the device’s permitted use across hospital and healthcare settings, creating a meaningful regulatory and intellectual-property asset. Its commercial value remains conditional because the company will not launch without clearance for its AI-ECG component.
Merger Financing SupportThe private placement provides additional working capital while HeartSciences advances the proposed combination with Fortitude. Capital from the prospective merger partner also demonstrates transaction support and may improve near-term financial flexibility during the closing process.
Bears Say
Severely Stressed Capital StructureNegative equity combined with very high debt materially weakens balance-sheet resilience and leaves little protection for creditors or shareholders. The historical swings in debt and equity also indicate persistent financing and solvency risk rather than a temporary capital imbalance.
Heavy Cash BurnStrongly negative operating and free cash flow show that the business is not self-funding and remains dependent on external capital. Continued cash consumption can constrain investment, increase financing needs, and make execution more vulnerable if funding conditions or transaction timing deteriorate.
Deep And Persistent LossesThe positive gross margin is overwhelmed by exceptionally large operating and net losses, leaving no demonstrated path to sustainable profitability in the reported results. Persistent losses reduce internal funding capacity and make future growth dependent on major improvement in scale, costs, or both.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $1.63 and its highest was $5.25 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $17.69M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Dec 21, 2026 which is in 60 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Sep 15, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.72 by -$0.14.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate is -0.62.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 4,843,910 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.72. Following the earnings report the stock price went down -2.825%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
HSCS Stock 12 Month Forecast
Average Price Target
$12.00
▲(300.00% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
10.41% Insiders
0.87% Mutual Funds
1.35% Other Institutional Investors
86.25% Public Companies and
Individual Investors